Cardiac Hypertrophy

Serca2a Overexpression Restores Normal Calcium Handling In Myocytes

Published in Gene Therapy Weekly, August 23rd, 2001

by Deborah W. Heinrich, PhD, staff medical writer - Those facing heart failure resulting from calcium handling abnormalities in myocytes may find new hope in a recent study in the journal Cell Calcium.

"Reductions in cardiac sarcoplasmic reticulum calcium-ATPase (Serca2a) levels are thought to underlie the prolonged calcium (Ca²⁺) transients and consequent reduced contractile performance seen in human cardiac hypertrophy and heart failure," explained A.M. Reilly and colleagues, University of Melbourne, Australia.

They found evidence of this when examining freshly isolated rat cardiac myocytes after inducing right ventricular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry